西黄胶囊在乳腺癌辅助治疗中的应用
发布时间：2018-11-25 08:21
【摘要】：目的:通过观察西黄胶囊辅助化疗治疗早期乳腺癌的疗效,对上肢水肿的发生是否有预防作用以及观察患者生活质量、免疫功能是否获益等,从而客观评价在乳腺癌的治疗过程西黄胶囊的使用是否有益。为乳腺癌的综合治疗提供临床支撑,提高乳腺癌患者总体生存质量及生理机能,并指导今后临床工作中的正确用药。方法:选择山西医科大学第二医院乳腺外科符合本研究纳入标准的乳腺癌术后患者60例,随机分为治疗组26例、对照组34例,治疗组在常规化疗、上肢功能锻炼基础上加入口服西黄胶囊,两组参与研究患者均采用AC-T(吡柔吡星+环磷酰胺-多西他赛)化疗方案8个周期,观察组加服西黄胶囊8粒/次,2次/天于手术后48小时开始使用,连用一周后停止,化疗的8个周期均以此方法用药。于治疗前、治疗4周、12周分别测定两组观察患者上肢水肿发生率情况、有关影响水肿相关因素以及生存质量、免疫功能等近期疗效来评价在乳腺癌全程化疗中西黄胶囊所发挥的作用。本研究采用SPSS19.0统计软件对实验数据进行统计并予以分析。结果1、上肢水肿改善情况:治疗组与对照组比较,P=0.9310.05.说明西黄胶囊在预防术后上肢水肿方面并未显示出明显优势。对水肿相关因素研究分析发现:BMI与上肢水肿发生率有关:P=0.0210.05,而年龄(P=0.1360.05)、淋巴结转移(P=0.4430.05)、患肢是否是受力侧(P=0.0730.05)与其无关。2、生活质量改善情况(KPS评分):治疗前两组KPS评分P0.05,两组间并无任何统计学差异。治疗后,治疗组P0.001,差别具有统计学意义。对照组P0.05,差异无意义。治疗后两组间比较P0.001,具有比较显著的统计学意义。3、免疫功能改善评价而言,分别于治疗前、治疗4周、12周检验两组免疫功能指标,后经t检验后显示P0.05,均无显著性差异。结论1、在乳腺癌全程化疗过程中辅助应用西黄胶囊对术后上肢水肿的发生并未起到预防及治疗的作用。与水肿相关影响因素分析显示,影响乳腺癌患者术后上肢淋巴水肿的独立危险因素便是体重指数(BMI),而年龄、淋巴结转移情况、患肢是否主力侧等与乳腺癌患者术后上肢水肿的发生无明显相关。2、辅助应用西黄胶囊能够不同程度的改善乳腺癌术后患者的KPS,提高患者体力状况及生活质量,适合临床应用并广泛推广;3、辅助应用西黄胶囊未能显示出对乳腺癌术后患者免疫细胞功能的调节。
[Abstract]:Objective: to observe the efficacy of Xihuang capsule in the treatment of early breast cancer, whether it has preventive effect on the occurrence of upper limb edema, and whether the patients' quality of life and immune function benefit. Therefore, objective evaluation in the treatment of breast cancer Xihuang capsule is useful. To provide clinical support for comprehensive treatment of breast cancer, improve the overall quality of life and physiological function of breast cancer patients, and guide the correct use of drugs in clinical work in the future. Methods: sixty breast cancer patients who met the criteria of breast surgery in the second Hospital of Shanxi Medical University were randomly divided into treatment group (n = 26) and control group (n = 34). On the basis of upper limb function exercise, Xihuang capsule was taken orally. Both patients in the study group were treated with AC-T chemotherapy regimen for 8 cycles, and the observation group received 8 capsules of Xihuang capsule every time. Two times a day, 48 hours after operation, and then stopped for one week. The eight cycles of chemotherapy were all used in this way. Before treatment, 4 weeks and 12 weeks of treatment, the incidence of upper limb edema, factors related to edema and quality of life were measured in the two groups. The short-term efficacy of immune function to evaluate the role of Huihuang capsule in the whole course of chemotherapy for breast cancer. In this study, SPSS19.0 statistical software was used to analyze the experimental data. Results 1. The improvement of upper limb edema: compared with the control group, the treatment group was 0.9310.05. It shows that Xihuang capsule has no obvious advantage in preventing edema of upper limb after operation. The analysis of the related factors of edema showed that BMI was related to the incidence of edema in upper extremity: P0. 0210.05, age (P0. 1360.05), lymph node metastasis (P0. 4433. 05), and the relationship between Edema and Edema (P0. 0210.05). (2) the improvement of quality of life (KPS score): before treatment, there was no significant difference in KPS score between the two groups (P 0.05). After treatment, the treatment group P 0.001, the difference was statistically significant. There was no significant difference in the control group (P 0.05). Compared with P0.001 after treatment, there was significant statistical significance between the two groups. 3. In the evaluation of immune function improvement, the immune function indexes of the two groups were tested before, 4 and 12 weeks of treatment, respectively, and then showed P0.05 after t test. There was no significant difference between the two groups. Conclusion 1. The application of Xihuang capsule in the whole course of breast cancer chemotherapy did not play a preventive and therapeutic role in the occurrence of upper limb edema after operation. The analysis of factors related to edema showed that the independent risk factors of lymphedema in upper limb of breast cancer patients after operation were body mass index (BMI),) age and lymph node metastasis. There was no significant correlation between the occurrence of edema in the upper limb of breast cancer patients and the main side of the affected limbs. 2. The application of Xihuang capsule can improve the KPS, of patients with breast cancer and improve their physical condition and quality of life in varying degrees. Suitable for clinical application and wide spread; 3. The adjuvant application of Xihuang capsule failed to show the regulation of immune cell function in postoperative breast cancer patients.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9
[Abstract]:Objective: to observe the efficacy of Xihuang capsule in the treatment of early breast cancer, whether it has preventive effect on the occurrence of upper limb edema, and whether the patients' quality of life and immune function benefit. Therefore, objective evaluation in the treatment of breast cancer Xihuang capsule is useful. To provide clinical support for comprehensive treatment of breast cancer, improve the overall quality of life and physiological function of breast cancer patients, and guide the correct use of drugs in clinical work in the future. Methods: sixty breast cancer patients who met the criteria of breast surgery in the second Hospital of Shanxi Medical University were randomly divided into treatment group (n = 26) and control group (n = 34). On the basis of upper limb function exercise, Xihuang capsule was taken orally. Both patients in the study group were treated with AC-T chemotherapy regimen for 8 cycles, and the observation group received 8 capsules of Xihuang capsule every time. Two times a day, 48 hours after operation, and then stopped for one week. The eight cycles of chemotherapy were all used in this way. Before treatment, 4 weeks and 12 weeks of treatment, the incidence of upper limb edema, factors related to edema and quality of life were measured in the two groups. The short-term efficacy of immune function to evaluate the role of Huihuang capsule in the whole course of chemotherapy for breast cancer. In this study, SPSS19.0 statistical software was used to analyze the experimental data. Results 1. The improvement of upper limb edema: compared with the control group, the treatment group was 0.9310.05. It shows that Xihuang capsule has no obvious advantage in preventing edema of upper limb after operation. The analysis of the related factors of edema showed that BMI was related to the incidence of edema in upper extremity: P0. 0210.05, age (P0. 1360.05), lymph node metastasis (P0. 4433. 05), and the relationship between Edema and Edema (P0. 0210.05). (2) the improvement of quality of life (KPS score): before treatment, there was no significant difference in KPS score between the two groups (P 0.05). After treatment, the treatment group P 0.001, the difference was statistically significant. There was no significant difference in the control group (P 0.05). Compared with P0.001 after treatment, there was significant statistical significance between the two groups. 3. In the evaluation of immune function improvement, the immune function indexes of the two groups were tested before, 4 and 12 weeks of treatment, respectively, and then showed P0.05 after t test. There was no significant difference between the two groups. Conclusion 1. The application of Xihuang capsule in the whole course of breast cancer chemotherapy did not play a preventive and therapeutic role in the occurrence of upper limb edema after operation. The analysis of factors related to edema showed that the independent risk factors of lymphedema in upper limb of breast cancer patients after operation were body mass index (BMI),) age and lymph node metastasis. There was no significant correlation between the occurrence of edema in the upper limb of breast cancer patients and the main side of the affected limbs. 2. The application of Xihuang capsule can improve the KPS, of patients with breast cancer and improve their physical condition and quality of life in varying degrees. Suitable for clinical application and wide spread; 3. The adjuvant application of Xihuang capsule failed to show the regulation of immune cell function in postoperative breast cancer patients.
【学位授予单位】：山西医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R737.9
【参考文献】
相关期刊论文 前10条
1 高苇;吴斌;郑璐;;乳腺癌的治疗现状与展望[J];中国医药指南;2016年18期
2 张长永;闫雷;李红;;西黄胶囊减轻肺癌化疗毒副反应的临床效果观察[J];广西医学;2016年05期
3 童一苇;陈小松;沈坤炜;;乳腺癌多学科诊治现状及进展[J];外科理论与实践;2016年02期
4 徐秋萍;胡文静;刘宝瑞;;西黄丸抗肿瘤作用的研究现状[J];癌症进展;2016年01期
5 芦琴;项景芳;张秉;;西黄丸/胶囊辅助治疗乳腺癌有效性和安全性Meta分析[J];中国老年学杂志;2015年24期
6 王黎;;西黄胶囊联合化疗治疗中晚期乳腺癌的疗效观察[J];中医药学报;2015年06期
7 张森;王e，
本文编号：2355431
本文链接：https://www.wllwen.com/yixuelunwen/zlx/2355431.html
